COST EFFECTIVENESS OF ZOLEDRONIC ACID IN THE PREVENTION OF SKELETAL RELATED EVENTS IN RENAL CELL CARCINOMA PATIENTS WITH BONE METASTASES: AN EXPLORATORY ANALYSIS FOR FRANCE

被引：0
|
作者：
Botteman, M. [1 ]
Stephens, J.
Foley, I.
Kaura, S. [2 ]
机构：
[1] Pharmerit N Amer LLC, Hlth Econ, Bethesda, MD USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：201 / 202
页数：2
相关论文
共 50 条
  • [31] Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.
    Shirina, N.
    Coleman, R. E.
    Chen, Y. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 475S - 475S
  • [32] RETROSPECTIVE DATABASE ANALYSIS OF ZOLEDRONIC ACID TREATMENT PATTERNS IN PATIENTS WITH RENAL CELL CARCINOMA OR BLADDER CANCER AND BONE METASTASES
    Kaura, S.
    Henk, H. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 64 - 64
  • [33] Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Saad, F
    Schulman, KA
    JOURNAL OF UROLOGY, 2004, 171 (04): : 1537 - 1542
  • [34] Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM)
    Rader, Michael E.
    Danese, Mark
    Cong, Ze
    Halperin, Marc
    Qian, Yi
    Goessl, Carsten Dietrich
    Chung, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [35] The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
    Zhang, Zhicai
    Pu, Feifei
    Shao, Zengwu
    JOURNAL OF BONE ONCOLOGY, 2017, 9 : 21 - 24
  • [36] Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study
    Abdel-Rahman, Omar
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 757 - 761
  • [37] Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (08) : 2000 - 2003
  • [38] Assessment of the cost-effectiveness of zoledronic acid in the management of skeletal metastases in lung cancer patients in France, Germany, and the United Kingdom
    Botteman, Marc F.
    Kaura, Satyin
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S542 - S543
  • [39] Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma
    Yasuda, Yosuke
    Fujii, Yasuhisa
    Yuasa, Takeshi
    Kitsukawa, Shinichi
    Urakami, Shinji
    Yamamoto, Shinya
    Yonese, Junji
    Takahashi, Shunji
    Fukui, Iwao
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (05) : 877 - 883
  • [40] Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma
    Yosuke Yasuda
    Yasuhisa Fujii
    Takeshi Yuasa
    Shinichi Kitsukawa
    Shinji Urakami
    Shinya Yamamoto
    Junji Yonese
    Shunji Takahashi
    Iwao Fukui
    International Journal of Clinical Oncology, 2013, 18 : 877 - 883
12345